SAB Biotherapeutics, Inc. Enters Material Manufacturing Agreement with Emergent BioSolutions Canada Inc.

Key Points for Investors

• Material Definitive Agreement Signed: SAB Biotherapeutics, Inc. (“SAB BIO”) has entered into a Master Services Agreement (MSA) with Emergent BioSolutions Canada Inc., signifying a major operational partnership for the manufacturing and supply of SAB’s drug products.
• Manufacturing Partnership: The agreement outlines that Emergent BioSolutions will provide manufacturing, formulation, processing, labeling, and quality control testing for SAB’s products under cGMP (current Good Manufacturing Practice) standards.
• Mutual Confidentiality: Both parties have agreed to customary mutual confidentiality obligations, protecting trade secrets, proprietary information, and manufacturing processes.
• Exclusive Rights and Assignment: The agreement includes provisions for exclusive rights, assignment to affiliates or third parties in the event of business transfer, and survival of key terms post-termination.
• Financial Impact: While specific financial terms are redacted, the agreement contains provisions for pricing adjustments based on justified cost increases and a “Minimum Annual Aggregate Spend” commitment by SAB, which could affect operating expenses and future cash flows.
• Risk Factors: The agreement includes detailed sections on indemnification, liability, insurance, and regulatory compliance, which are critical for investors to understand potential exposures and obligations.
• Securities Disclosure: SAB’s common stock (\$0.0001 par value, trading symbol: SABS) and related warrants (trading symbol: SABSW) are listed on Nasdaq. The company identifies as an emerging growth company under the Exchange Act.
• Forward-Looking Statements: The company highlights that statements about FDA approval and the future development of SAB-142 and other products are forward-looking and subject to significant risks and uncertainties.

Details Shareholders Need to Know

This agreement is a significant operational milestone for SAB Biotherapeutics as it formalizes a commercial-scale manufacturing partnership with Emergent BioSolutions Canada Inc., a well-known player in the biomanufacturing sector. Such partnerships are critical for advancing drug candidates toward regulatory approval and commercial launch, particularly in the complex biologics space. The agreement’s scope covers the entire manufacturing process, including quality control, regulatory documentation, and support for regulatory filings—key steps for potential FDA approval.

The MSA contains several price-sensitive provisions:

• Minimum Annual Spend: SAB commits to a minimum level of manufacturing spend with Emergent each year, which could affect operating costs and cash management for the company.
• Price Adjustments: Emergent can adjust pricing with written justification, potentially impacting future cost structures for SAB.
• Termination Rights: The agreement can be terminated under specific circumstances, including insolvency, breach, or regulatory non-compliance, with survival clauses for indemnification and confidentiality—critical for risk assessment.
• Confidentiality and IP: The agreement strictly protects confidential information and IP, and any breach or misappropriation could have material consequences.

Potential Impact on Share Value

This definitive manufacturing partnership directly supports SAB’s ability to scale production for clinical and potential commercial use, a prerequisite for regulatory submissions and eventual product sales. The agreement also enhances the company’s credibility with regulators and potential partners, and may be viewed positively by investors. Any disruption, cost overrun, or material breach could have a negative impact, while successful execution could accelerate SAB’s time-to-market and revenue generation, driving share price appreciation.

Other Notable Provisions

• Either party can assign the agreement to affiliates or as part of a business transaction, but not otherwise without consent.
• Detailed protocols for handling confidential information, including destruction or return upon agreement termination.
• Survival of key indemnification, liability, and confidentiality clauses after termination.
• Both parties are required to carry insurance and comply with all regulatory requirements.
• Emergent’s cost for recalls, product liability, or regulatory action is limited unless gross negligence is proven.

Forward-Looking Statements and Risks

Investors should note that statements regarding potential FDA approval, SAB-142 development, and other future events are forward-looking and subject to substantial risk. Actual outcomes may differ due to regulatory, operational, or market factors. SAB Biotherapeutics expressly disclaims any obligation to update these statements except as required by law.

Conclusion

The execution of this MSA is a major step forward in SAB Biotherapeutics’ journey toward commercializing its product pipeline. Investors should closely monitor future disclosures for details on financial terms, manufacturing milestones, and regulatory progress, as these will materially impact valuation and share performance.